# Regulation of inhibitory DAMP to harness immunogenic cell death

> **NIH NIH F31** · CEDARS-SINAI MEDICAL CENTER · 2020 · $45,520

## Abstract

PROJECT SUMMARY
Most anti-cancer therapies designate cell death as the ultimate end goal. Yet, the fascinating biology beyond cell
death is emerging as an important contributor to therapeutic outcome. A clinically-relevant example is
immunogenic cell death (ICD)—characterized by its functional capacity to potentiate antitumoral T cell immunity.
The current defining molecular hallmark of ICD is the release of damage-associated molecular patterns (DAMPs),
which function as “danger” signals to ultimately activate T cell immunity. However, our preliminary findings
revealed that successful DAMP release alone was insufficient to promote ICD; leading us to challenge this
dogma and reason that additional regulatory component(s), other than DAMPs, influence the immunogenicity of
cell death. Herein, our new findings also revealed that an inhibitory DAMP (iDAMP) with unclear upstream
regulatory mechanisms was concurrently released by dying cells as a physiologic response to chemotherapeutic
treatment. Intriguingly, the pharmacological intervention to preclude iDAMP release by dying cells relieved the
immunosuppressive constraints imposed by the iDAMP, and readily enabled a non-immunogenic chemotherapy
to elicit an antitumoral T cell response. We now propose to elucidate 1) the unexplored upstream regulatory
mechanism(s) of the iDAMP and 2) iDAMP blockade as a generalizable strategy to augment antitumoral T cell
immunity. Our underlying hypothesis is that pharmacological intervention of the iDAMP axis poses as a
paradigm-shifting approach to augment antitumoral T cell immunity and therapeutic efficacy. Knowledge gained
from the proposed research will elucidate the upstream mechanism in epithelial cancer cells that regulates
iDAMP biosynthesis and release as a physiologic response to anti-cancer therapy, as well as evaluate a
therapeutic approach that can alleviate the immunosuppressive constraints of the iDAMP to augment antitumoral
T cell immunity. The success of the proposed research will yield a compelling scientific rationale to move the
field forward by translating our preclinical findings into clinical application.

## Key facts

- **NIH application ID:** 9911207
- **Project number:** 1F31CA247257-01
- **Recipient organization:** CEDARS-SINAI MEDICAL CENTER
- **Principal Investigator:** Kazukuni Hayashi
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $45,520
- **Award type:** 1
- **Project period:** 2020-02-24 → 2023-02-23

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9911207

## Citation

> US National Institutes of Health, RePORTER application 9911207, Regulation of inhibitory DAMP to harness immunogenic cell death (1F31CA247257-01). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9911207. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*